Wall Street brokerages expect Neuronetics Inc (NASDAQ:STIM) to post earnings per share (EPS) of ($0.36) for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Neuronetics’ earnings. The lowest EPS estimate is ($0.37) and the highest is ($0.35). The company is expected to report its next earnings report on Tuesday, February 5th.
On average, analysts expect that Neuronetics will report full-year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.11) to ($1.66). For the next financial year, analysts forecast that the business will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.29) to ($1.18). Zacks’ earnings per share averages are a mean average based on a survey of analysts that cover Neuronetics.
Neuronetics (NASDAQ:STIM) last issued its earnings results on Tuesday, November 6th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.11. The company had revenue of $13.74 million during the quarter, compared to the consensus estimate of $12.68 million.
STIM has been the topic of several recent analyst reports. Zacks Investment Research raised Neuronetics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Saturday. BTIG Research reaffirmed a “buy” rating and issued a $33.00 price target on shares of Neuronetics in a report on Wednesday. JMP Securities raised their price target on Neuronetics from $36.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, August 15th. Canaccord Genuity raised their price target on Neuronetics from $33.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, August 15th. Finally, William Blair initiated coverage on Neuronetics in a report on Monday, July 23rd. They issued an “outperform” rating on the stock. Six analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus price target of $34.50.
NASDAQ STIM traded down $0.70 during trading hours on Friday, hitting $24.75. The company had a trading volume of 78,786 shares, compared to its average volume of 103,428. Neuronetics has a 52 week low of $20.70 and a 52 week high of $39.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.59 and a current ratio of 7.63.
Several hedge funds and other institutional investors have recently made changes to their positions in STIM. Victory Capital Management Inc. purchased a new position in shares of Neuronetics during the 2nd quarter valued at about $133,000. American International Group Inc. bought a new position in Neuronetics during the 3rd quarter worth approximately $136,000. Pier Capital LLC bought a new position in Neuronetics during the 2nd quarter worth approximately $186,000. Alpine Woods Capital Investors LLC purchased a new position in Neuronetics during the second quarter valued at $266,000. Finally, United Services Automobile Association purchased a new position in Neuronetics during the second quarter valued at $266,000. 60.76% of the stock is currently owned by institutional investors.
Neuronetics Company Profile
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
Read More: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.